PP405
Also known as: JXL-069
MPC Inhibitor | Hair Follicle Stem Cell Activation
Overview
PP405 is an investigational topical drug developed by Pelage Pharmaceuticals for the treatment of androgenetic alopecia. Based on research conducted at UCLA, PP405 works through a fundamentally different mechanism than existing hair loss treatments: rather than blocking androgens like finasteride or promoting blood flow like minoxidil, it targets the metabolic dormancy of hair follicle stem cells directly. By inhibiting the mitochondrial pyruvate carrier (MPC1/MPC2), PP405 causes pyruvate accumulation in hair follicle stem cells, stimulating lactate dehydrogenase activity and triggering a metabolic shift that reactivates dormant follicles. Phase 2a clinical trial results showed increased hair count and thickness with a 0.05% gel formulation applied once daily. As of 2025, the drug has completed Phase 2a trials, with Phase 3 trials planned for 2026.
Key benefits
- Novel non-hormonal mechanism of action targeting hair follicle stem cell metabolism
- Directly addresses the root cause of follicle dormancy rather than downstream hormonal effects
- Potentially effective regardless of androgen status, broadening the treatable population
- Topical application (0.05% gel) limits systemic exposure
- Phase 2a results demonstrated increased hair count and thickness
- Compatible with existing hair loss treatments (finasteride, minoxidil) for combination therapy
- No known sexual or hormonal side effects based on available trial data
Mechanism of action
PP405 is a dual inhibitor of the mitochondrial pyruvate carrier complex, targeting both the MPC1 and MPC2 subunits. Under normal conditions, the MPC transports pyruvate from the cytoplasm into the mitochondrial matrix, where it enters the tricarboxylic acid (TCA) cycle for oxidative metabolism. In hair follicle stem cells (HFSCs), this standard metabolic pathway is associated with quiescence and dormancy. By blocking MPC1/MPC2, PP405 prevents pyruvate from entering the mitochondria, causing it to accumulate in the cytoplasm. This pyruvate buildup stimulates lactate dehydrogenase (LDH) activity, which converts pyruvate to lactate, shifting the cell's metabolic profile toward aerobic glycolysis. This metabolic reprogramming mimics the signaling environment that naturally triggers HFSCs to exit quiescence and re-enter the cell cycle. The activated stem cells then initiate a new anagen (growth) phase in dormant hair follicles. Critically, this mechanism is entirely independent of the androgen/DHT pathway targeted by finasteride and dutasteride, and distinct from the vasodilatory effects of minoxidil, meaning PP405 could be effective regardless of a patient's androgen status.
Molecular data
- Type
- Small molecule mitochondrial pyruvate carrier (MPC) inhibitor
- Half-life
- Topical application; exact pharmacokinetics not published
Indications
What the research community uses this compound for, with self-reported effectiveness.
Hair Loss
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 0.05% gel | Once daily | — |
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Scalp irritation at the application site
- Application site reactions (redness, dryness, itching)
Rare side effects
- Long-term safety data not yet available (Phase 2 stage)
- Systemic effects not characterized due to limited clinical data
Contraindications
- Known hypersensitivity to PP405 or any component of the gel formulation
- Full contraindication profile has not been established (investigational drug)
- Pregnant or breastfeeding women should avoid use until safety data is available
References
Primary literature and clinical-trial data informing this entry.